Reconsidering the role of blood-brain barrier in Alzheimer's disease: From delivery to target

被引:21
|
作者
Sousa, Joao Andre [1 ]
Bernardes, Catarina [1 ]
Bernardo-Castro, Sara [1 ,2 ]
Lino, Miguel [3 ]
Albino, Ines [3 ]
Ferreira, Lino [2 ,3 ]
Bras, Jose [4 ]
Guerreiro, Rita [4 ]
Tabuas-Pereira, Miguel [1 ,2 ]
Baldeiras, Ines [2 ,5 ]
Santana, Isabel [1 ,2 ,5 ]
Sargento-Freitas, Joao [1 ,2 ,3 ,5 ]
机构
[1] Ctr Hosp & Univ Coimbra, Dept Neurol, Coimbra, Portugal
[2] Univ Coimbra, Fac Med, Coimbra, Portugal
[3] Univ Coimbra, Ctr Neurosci & Cell Biol, Coimbra, Portugal
[4] Van Andel Inst, Dept Neurodegenerat Sci, Grand Rapids, MI USA
[5] Univ Coimbra, Ctr Innovat Biomed & Biotechnol CIBB, Coimbra, Portugal
来源
关键词
blood-brain barrier; nanomaterials; Alzheimer's disease; neurodegenerative diseases; amyloid clearance; genetic targeting; AMYLOID-BETA; MOUSE MODEL; NEUROVASCULAR DYSFUNCTION; DRUG-DELIVERY; THERAPEUTIC STRATEGIES; COGNITIVE IMPAIRMENT; P-GLYCOPROTEIN; CLEARANCE; RAGE; FLOW;
D O I
10.3389/fnagi.2023.1102809
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The existence of a selective blood-brain barrier (BBB) and neurovascular coupling are two unique central nervous system vasculature features that result in an intimate relationship between neurons, glia, and blood vessels. This leads to a significant pathophysiological overlap between neurodegenerative and cerebrovascular diseases. Alzheimer's disease (AD) is the most prevalent neurodegenerative disease whose pathogenesis is still to be unveiled but has mostly been explored under the light of the amyloid-cascade hypothesis. Either as a trigger, bystander, or consequence of neurodegeneration, vascular dysfunction is an early component of the pathological conundrum of AD. The anatomical and functional substrate of this neurovascular degeneration is the BBB, a dynamic and semi-permeable interface between blood and the central nervous system that has consistently been shown to be defective. Several molecular and genetic changes have been demonstrated to mediate vascular dysfunction and BBB disruption in AD. The isoform epsilon 4 of Apolipoprotein E is at the same time the strongest genetic risk factor for AD and a known promoter of BBB dysfunction. Low-density lipoprotein receptor-related protein 1 (LRP-1), P-glycoprotein, and receptor for advanced glycation end products (RAGE) are examples of BBB transporters implicated in its pathogenesis due to their role in the trafficking of amyloid-beta. This disease is currently devoid of strategies that change the natural course of this burdening illness. This unsuccess may partly be explained by our misunderstanding of the disease pathogenesis and our inability to develop drugs that are effectively delivered to the brain. BBB may represent a therapeutic opportunity as a target itself or as a therapeutic vehicle. In this review, we aim to explore the role of BBB in the pathogenesis of AD including the genetic background and detail how it can be targeted in future therapeutic research.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Immunotherapy and neuroimmunology in Alzheimer's disease: a perspective from the blood-brain barrier
    Banks, William A.
    IMMUNOTHERAPY, 2010, 2 (01) : 1 - 3
  • [22] Interactions between glial cells and the blood-brain barrier and their role in Alzheimer's disease
    Zhao, Ming
    Jiang, Xue-Fan
    Zhang, Hui-Qin
    Sun, Jia-Hui
    Pei, Hui
    Ma, Li-Na
    Cao, Yu
    Li, Hao
    AGEING RESEARCH REVIEWS, 2021, 72
  • [23] From the gut to the blood-brain barrier: Novel approaches for the treatment and targeted delivery of therapeutics in Alzheimer's disease
    Nicolazzo, Joseph A.
    Abasszade, Joshua H.
    ADVANCED DRUG DELIVERY REVIEWS, 2023, 196
  • [24] Microbiota-gut-brain axis and Alzheimer's disease: Implications of the blood-brain barrier as an intervention target
    Liu, Shan
    Gao, Jiguo
    Liu, Kangding
    Zhang, Hong-Liang
    MECHANISMS OF AGEING AND DEVELOPMENT, 2021, 199
  • [25] Effects of oxysterols on the blood-brain barrier: Implications for Alzheimer's disease
    Gosselet, Fabien
    Saint-Pol, Julien
    Fenart, Laurence
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2014, 446 (03) : 687 - 691
  • [26] Amyloid angiopathy and blood-brain barrier changes in Alzheimer's disease
    Wisniewski, HM
    Vorbrodt, AW
    Wegiel, J
    CEREBROVASCULAR PATHOLOGY IN ALZHEIMER'S DISEASE, 1997, 826 : 161 - 172
  • [27] Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance
    Nehra, Geetika
    Bauer, Bjoern
    Hartz, Anika M. S.
    PHARMACOLOGY & THERAPEUTICS, 2022, 234
  • [28] Dysfunction of the blood-brain barrier in Alzheimer's disease: Evidence from human studies
    Kurz, Carolin
    Walker, Lauren
    Rauchmann, Boris-Stephan
    Perneczky, Robert
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2022, 48 (03)
  • [29] Transport of drugs across the blood-brain barrier in Alzheimer's disease
    Nicolazzo, Joseph A.
    Mehta, Dharmini C.
    THERAPEUTIC DELIVERY, 2010, 1 (04) : 595 - 611
  • [30] Dyslipidemia in Alzheimer's Disease Is Associated with Blood-Brain Barrier Impairment
    Bowman, Gene L.
    Kaye, Jeffery A.
    Quinn, Joseph F.
    NEUROLOGY, 2010, 74 (09) : A137 - A137